secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0001104659-25-069169
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent projects topline phase 3 FURVENT data for firmonertinib in early 2026
------------------------------------------------------------------------------

- Topline firmonertinib monotherapy data from pivotal Phase 3 FURVENT study in 1L NSCLC EGFR exon20ins projected early 2026.
- Primary endpoint is progression-free survival by blinded independent central review per RECIST 1.1.
- Enrollment in the global FURVENT study completed in Q1 2025.
- Firmonertinib previously received FDA Breakthrough Therapy Designation for this patient population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925069169/0001104659-25-069169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925069169/tm2521271d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-069169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer